Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 8/20 | 0.60 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.42 |
| ▸ | ASPH | Q12797 | 1/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641922 | 0.96 | EGLN3 (0.58) | EGLN3EGLN1POLBEGLN2CNR1 | |
| SCHEMBL1640596 | 0.95 | EGLN3 (0.57) | EGLN3EGLN1POLBEGLN2CNR1 | |
| Ammonia Solution, Strong SCHEMBL1641819 | 0.94 | EGLN3 (0.56) | EGLN3EGLN1POLBEGLN2CNR1 | |
| SCHEMBL1641768 | 0.88 | EGLN3 (0.74) | EGLN3EGLN1EGLN2HIF1AMEN1 | |
| SCHEMBL12727318 | 0.88 | EGLN3 (0.74) | EGLN3EGLN1EGLN2HIF1AMEN1 | |
| SCHEMBL12727372 | 0.86 | EGLN3 (0.51) | EGLN3EGLN1EGLN2CNR1CNR2 | |
| SCHEMBL1641990 | 0.86 | EGLN3 (0.62) | EGLN3EGLN1EGLN2HIF1AMEN1 | |
| SCHEMBL1641809 | 0.86 | EGLN3 (0.65) | EGLN3EGLN1EGLN2HIF1AMEN1 | |
| SCHEMBL1641432 | 0.85 | EGLN3 (0.64) | EGLN3EGLN1EGLN2HIF1AMEN1 | |
| SCHEMBL1642088 | 0.85 | EGLN3 (0.70) | EGLN3EGLN1EGLN2HIF1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| WO-2009158315-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098324-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885EGLN1 6/4885POLB 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.